



*For buying options or licensing agreements
contact Joe D'Antonio at 315-807-7459 - dantonio.joseph@yahoo.com*

CLIENT: Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

OBJECTIVE:

According to the World Health Organization (WHO), as many as 10 million people worldwide contract lethal diseases every year through the use of contaminated needles. 1.8 million people infected by contaminated needles, mostly children, die from the effects, about 1 every 20 seconds. WHO estimates that about half of injections in the developing world are provided with unsterilized or reused needles.

These estimates suggest that reused needles cause millions of blood-borne infections each year with billions of dollars (USD) in direct medical costs. Needle reuse, poorly administered injections and accidental needle-sticks expose millions to the risk of infection with blood-borne pathogens such as hepatitis B, hepatitis C, and HIV.

Developing countries have begun addressing injection safety concerns by introducing single-dose, non-reusable, disposable syringes for vaccinations with Disposable Syringe Jet Injection (DSJI) devices. The risks of transmitting chronic infections by needle-stick injury from sharps waste continue to be a leading hazard for healthcare workers and waste disposal personnel.

LectraJet® seeks to eliminate this significant health risk through the effective use of our propriety DSJI technology.

SOLUTION:

The vision for LectraJet® is to develop new products encompassing innovative, proprietary IP technologies applied to addressing unique, serious medical conditions in established and emerging markets, bringing high rates of return. Since 1992, LectraJet® has been engaged in the research, development, design engineering and testing of high-speed, battery-powered and manual DSJI injection systems through LectraJet®, LLC.

The battery-powered injection systems include the LectraJet® HSE for use in human mass immunization campaigns and the LectraVet® for high-speed or routine animal health

applications. The LectraJet® M4-RA was developed as a low-cost manual device designed for routine human injections when the requirement for speed is not a factor. LectraJet® needle-free technology includes both single and variable-dose applications for IM, SQ vaccines, drugs, insulin and ID/antigen-sparing needle-free injections.

LectraJet® core technology and research are leveraged over a number of medical applications using patented, specific electrical and mechanical technologies applied to significant medical conditions. The LectraJet® technology will be used to help manage serious medical conditions, including but not limited to, the need for mass immunization in the case of an avian/swine influenza pandemic, rapid deployment response to bioterrorism attacks and worldwide vaccine/immunization programs. The current LectraJet® M4-RA design is suitable for hospitals, clinics, physician offices, retail pharmacy, and other healthcare environments where routine injections are delivered.

LectraJet® has been the subject of contracts with the Centers for Disease Control and Prevention (CDC) and addresses urgent international health issues that are a major priority for the CDC, Department of Health and Human Services (DHHS), Department of Homeland Security (DHS), World Health Organization (WHO), National Institute of Health (NIH), Pan American Health Organization (PAHO), the Program for Appropriate Technology in Health (PATH), the Center for Vaccine Development (CVD), and the Department of Defense (DoD).